Grifols (NASDAQ:GRFS) Sets New 52-Week Low – Should You Sell?

Grifols, S.A. (NASDAQ:GRFS) hit a new 52-week low during mid-day trading on Monday . The company traded as low as $7.37 and last traded at $7.3750, with a volume of 326041 shares changing hands. The stock had previously closed at $7.64.

Analyst Ratings Changes

Several research firms recently commented on GRFS. Wall Street Zen downgraded shares of Grifols from a “buy” rating to a “hold” rating in a research report on Monday, May 18th. Weiss Ratings raised shares of Grifols from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Friday, May 8th. Finally, Zacks Research lowered shares of Grifols from a “hold” rating to a “strong sell” rating in a report on Friday, May 8th. Three analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Grifols has a consensus rating of “Reduce” and an average price target of $10.00.

Grifols Trading Down 0.4%

The company has a quick ratio of 0.85, a current ratio of 2.47 and a debt-to-equity ratio of 1.16. The company has a market cap of $4.98 billion, a price-to-earnings ratio of 38.42, a PEG ratio of 0.28 and a beta of 0.65. The firm has a 50 day moving average price of $8.04 and a two-hundred day moving average price of $8.58.

Grifols (NASDAQ:GRFS) last announced its earnings results on Saturday, February 14th. The biotechnology company reported $0.38 EPS for the quarter. The business had revenue of $2.32 billion for the quarter. Grifols had a return on equity of 6.21% and a net margin of 5.54%. As a group, equities analysts forecast that Grifols, S.A. will post 1.06 earnings per share for the current year.

Institutional Investors Weigh In On Grifols

Institutional investors have recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. increased its stake in Grifols by 25.7% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,928 shares of the biotechnology company’s stock valued at $55,000 after purchasing an additional 1,212 shares in the last quarter. Allworth Financial LP boosted its position in shares of Grifols by 15.7% during the 4th quarter. Allworth Financial LP now owns 8,073 shares of the biotechnology company’s stock worth $75,000 after purchasing an additional 1,096 shares in the last quarter. EverSource Wealth Advisors LLC grew its stake in shares of Grifols by 127.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 8,219 shares of the biotechnology company’s stock valued at $74,000 after buying an additional 4,604 shares during the period. PNC Financial Services Group Inc. grew its stake in shares of Grifols by 109.8% in the 3rd quarter. PNC Financial Services Group Inc. now owns 8,634 shares of the biotechnology company’s stock valued at $86,000 after buying an additional 4,518 shares during the period. Finally, Ameriprise Financial Inc. bought a new stake in Grifols in the 2nd quarter valued at about $95,000.

Grifols Company Profile

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.